Boston Immune Technologies and Therapeutics

1 clinical trials · Sponsor

Record	Firm	Date
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System (NCT06385522)	Boston Immune Technologies and Therapeutics	2025-08-01

Every clearance here is in the API, with alerts when new ones post.